Search

Pharmagest Interactive

Open

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Income

17M

Sales

116M

P/E

Sector Avg

14.895

Dividend yield

3.54

Profit margin

14.879

Employees

1,400

EBITDA

116M

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.54%

Next Earnings

30 mar 2026

Market Stats

By TradingEconomics

Market Cap

535M

Previous open

0

Previous close

0

Pharmagest Interactive Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 mar 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Market Talk
Major News Events

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Major News Events

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Market Talk
Earnings
Major News Events

Basic Materials Roundup: Market Talk

Pharmagest Interactive Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pharmagest Interactive

Equasens Société anonyme provides healthcare IT solutions in Europe. The company develops electronic equipment, digital and robotic health, and equipment lease financing solutions. It also offers id., a pharmacy management software suite; id. PATIENT for the exchange of healthcare data; id. VENTE, which facilitates and secures prescription sales; id. COMMANDE, which manages orders and inventory; dispensing robots; Ségur id. services; FARMACLICK, a communication protocol; DIFARM, a modular solution for wholesalers-distributors; and PHARE, a retail management tool. In addition, the company offers patient medication adherence, patient loyalty, point-of-sale commercial performance, piloting pharmacy operations, pharmacy team training, securing pharmacy operations and health data, and digital communication solutions; and in-home nursing services and hospital-at-home, hospitals, and telemedicine solutions. Further, it provides id. DESK, an informative and interactive dashboard; id. UP!, a smartphone app; id. EASYQ, a queuing management solution; Miaterapia, a patient app; and MediStory for tracking patient records; ExpressVitale module; and MEDILINK, a health data hosting provider. Additionally, the company offers KAP&LINK2, a terminal with smart card and NFC reader; eS-KAP-Ad, a mobile device with a pre-loaded software; KAP-INSIDE, a mobile terminal; TI-KAP, which allows access to contact and contactless cards; AUTHENTIFICATEUR, a patented patient authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; and NOVIAcare, which analyzes the behavior and activity of the elderly. It serves nursing homes, hospitals, in-house nursing care and hospital-at-home programs, regional health professional communities, multidisciplinary group practices, and individual healthcare professionals. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
help-icon Live chat